Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate EC-18 for Oral Mucositis in Patients With Concomitant Chemoirradiation for Cancers of the Mouth, Oropharynx, Hypopharynx and Nasopharynx

Trial Profile

Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate EC-18 for Oral Mucositis in Patients With Concomitant Chemoirradiation for Cancers of the Mouth, Oropharynx, Hypopharynx and Nasopharynx

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Aug 2017

At a glance

  • Drugs EC 18 (Primary)
  • Indications Hypopharyngeal cancer; Nasopharyngeal cancer; Orofacial cancer; Oropharyngeal cancer; Squamous cell cancer
  • Focus Adverse reactions
  • Sponsors Enzychem Lifesciences Corporation
  • Most Recent Events

    • 02 Aug 2017 According to an Enzychem Lifesciences Corporation media release, FDA has granted the company to start this phase II trial.
    • 30 Jun 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top